<h4>Purpose</h4>Peripheral blood immuno-inflammatory biomarkers (IIBs) may help predict response to neoadjuvant chemotherapy (NAC) and prognosis in HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.